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Therapies based on genetically modified cells hold great promise for the treatment of various diseases with often 
limited treatment options. Last year, Strimvelis, consisting of CD34+ hematopoietic stem cells equipped with the 
correct version of the ADA gene for the treatment of the severe combined immunodeficiency condition ADA-SCID, 
has received marketing authorization in the European Union. Convincing clinical success has also been observed 
with recombinant chimeric antigen receptor expressing T-cells used to treat patients suffering from B-cell 
malignancies.  
 
In respect to manufacturing and quality control, however, genetically modified cells are considered to be most 
complex medicinal products. Not only cell procurement, cultivation and genetic modification of the cells and their 
release testing needs particular consideration, also the vector used to deliver the modifying genetic sequence 
requires suitable design and proper manufacturing.  
 
In this presentation, these fundamental steps in cell therapy manufacturing will be discussed from a regulatory 
perspective. Challenges regarding process consistency and manufacturing process comparability, as well as 
GMP expectations will be highlighted. Furthermore, a brief overview of the European regulatory landscape for cell 
therapies and novel developments in their regulation will be given.  
 
